Actio Biosciences: Funding, Investors & Team (Oct 2026)
Actio Biosciences focuses on creating treatments for both rare and common diseases using genetics-oriented approaches. By utilizing human genetic insights and precision medicine techniques, the company identifies potential drug targets and is currently developing treatments for Charcot-Marie-Tooth disease type 2C and KCNT1-related epilepsy. Actio Biosciences conducts preclinical and Phase 1 studies to assess the safety, tolerability, and pharmacokinetics of their leading programs. In addition, the company collaborates with others, licenses technologies, and plans clinical trials to accelerate the development of treatments and potentially expand into more prevalent diseases.
Actio Biosciences has raised $66.0M across 1 funding round on record, the most recent a Series B of $66.0M announced in Jun 2025.
That round is above the $8.4M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Actio Biosciences Company Profile and Key Stats
Latest funding round on record: Jun 2025.
Actio Biosciences Funding Rounds
Actio Biosciences Founders and Leadership Team
No contact details are on record for this team yet.
Actio Biosciences Funding Compared to Other Biotechnology Startups
Actio Biosciences' latest round of $66.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Actio Biosciences in Biotechnology and San Diego
Companies Similar to Actio Biosciences
Prolific Machines is a biotech company located in San Francisco, California, that was established in 2020. It…
Altay Therapeutics is a biotech company focused on finding and discovering small molecule therapies for…
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Actio Biosciences Funding FAQs
What does Actio Biosciences do?
Actio Biosciences focuses on creating treatments for both rare and common diseases using genetics-oriented approaches. By utilizing human genetic insights and precision medicine techniques, the company identifies potential drug targets and is currently developing treatments for Charcot-Marie-Tooth disease type 2C and KCNT1-related epilepsy. Actio Biosciences conducts preclinical and Phase 1 studies to assess the safety, tolerability, and pharmacokinetics of their leading programs. In addition, the company collaborates with others, licenses technologies, and plans clinical trials to accelerate the development of treatments and potentially expand into more prevalent diseases.
How much funding has Actio Biosciences raised?
Actio Biosciences has raised $66.0M across 1 round on record. The most recent is a Series B of $66.0M announced in Jun 2025.
When did Actio Biosciences last raise funding?
Actio Biosciences' most recent funding round on record is a Series B of $66.0M, announced in Jun 2025.
Who founded Actio Biosciences?
FundedIQ lists David Goldstein (Founder) at Actio Biosciences.
Where is Actio Biosciences headquartered?
Actio Biosciences is based in San Diego, California, United States.
How many employees does Actio Biosciences have?
Actio Biosciences is in the 11-50 employee band.
How does Actio Biosciences' funding compare to other Biotechnology startups?
Actio Biosciences' latest round of $66.0M is above the $8.4M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Actio Biosciences Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Actio Biosciences is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.